863884-77-9

863884-77-9 structure

Name: Deleobuvir
Chemical Name: Deleobuvir
CAS Number: 863884-77-9
Molecular Formula: C₃₄H₃₃BrN₆O₃
Molecular Weight: 653.568
Catalog: Signaling Pathways Anti-infection HCV
Create Date: 2020-01-19 20:18:27
Modify Date: 2024-01-20 06:27:58
Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity; demonstrates subgenomic antiviral activity against GT1b and GT1a with EC50 of 11 and 23 nM in cell-based replicon assays; shows weak or no inhibition in specificity assays that include poliovirus RdRp, mammalian DdRp II, and DNA polymerase α, β, and γ; displays good antiviral potency and tolerability in early clinical trials of short-term treatment either as a single agent or in combination with pegylated IFN-α2a/ribavirin in HCV GT1 patients. HCV Infection Phase 3 Clinical

Name	Deleobuvir
Synonyms	2-Propenoic acid, 3-[2-[1-[[[2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- 58BU988K90 BI 207127 (2E)-3-{2-[1-({[2-(5-Bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl]carbonyl}amino)cyclobutyl]-1-methyl-1H-benzimidazol-6-yl}acrylic acid Deleobuvir

Description	Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity; demonstrates subgenomic antiviral activity against GT1b and GT1a with EC50 of 11 and 23 nM in cell-based replicon assays; shows weak or no inhibition in specificity assays that include poliovirus RdRp, mammalian DdRp II, and DNA polymerase α, β, and γ; displays good antiviral potency and tolerability in early clinical trials of short-term treatment either as a single agent or in combination with pegylated IFN-α2a/ribavirin in HCV GT1 patients. HCV Infection Phase 3 Clinical
References	References 1. Zeuzem S, et al. Gastroenterology. 2011 Dec;141(6):2047-55; quiz e14. 2. Zeuzem S, et al. Antivir Ther. 2013;18(8):1015-9. 3. Larrey D, et al. Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35. 4. LaPlante SR, et al. J Med Chem. 2014 Mar 13;57(5):1845-54. View Related Products by Target HCV HCV Infection